Hartman Institute for Therapeutic Organ Regeneration

VEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.

TitleVEGF-A stimulates ADAM17-dependent shedding of VEGFR2 and crosstalk between VEGFR2 and ERK signaling.
Publication TypeJournal Article
Year of Publication2008
AuthorsSwendeman S, Mendelson K, Weskamp G, Horiuchi K, Deutsch U, Scherle P, Hooper A, Rafii S, Blobel CP
JournalCirc Res
Volume103
Issue9
Pagination916-8
Date Published2008 Oct 24
ISSN1524-4571
KeywordsADAM Proteins, ADAM10 Protein, ADAM17 Protein, Amyloid Precursor Protein Secretases, Animals, Chlorocebus aethiops, COS Cells, Endothelial Cells, Extracellular Signal-Regulated MAP Kinases, Fibroblasts, Humans, Membrane Proteins, Mice, Mice, Knockout, Neuropilin-1, Recombinant Fusion Proteins, Signal Transduction, Swine, Time Factors, Transfection, Vascular Endothelial Growth Factor A, Vascular Endothelial Growth Factor Receptor-2
Abstract

<p>Vascular endothelial growth factor (VEGF)-A and the VEGF receptors are critical for regulating angiogenesis during development and homeostasis and in pathological conditions, such as cancer and proliferative retinopathies. Most effects of VEGF-A are mediated by the VEGFR2 and its coreceptor, neuropilin (NRP)-1. Here, we show that VEGFR2 is shed from cells by the metalloprotease disintegrin ADAM17, whereas NRP-1 is released by ADAM10. VEGF-A enhances VEGFR2 shedding by ADAM17 but not shedding of NRP-1 by ADAM10. VEGF-A activates ADAM17 via the extracellular signal-regulated kinase (ERK) and mitogen-activated protein kinase pathways, thereby also triggering shedding of other ADAM17 substrates, including tumor necrosis factor alpha, transforming growth factor alpha, heparin-binding epidermal growth factor-like growth factor, and Tie-2. Interestingly, an ADAM17-selective inhibitor shortens the duration of VEGF-A-stimulated ERK phosphorylation in human umbilical vein endothelial cells, providing evidence for an ADAM17-dependent crosstalk between the VEGFR2 and ERK signaling. Targeting the sheddases of VEGFR2 or NRP-1 might offer new opportunities to modulate VEGF-A signaling, an already-established target for treatment of pathological neovascularization.</p>

DOI10.1161/CIRCRESAHA.108.184416
Alternate JournalCirc Res
PubMed ID18818406
PubMed Central IDPMC2574836
Grant List / HHMI / Howard Hughes Medical Institute / United States
R01 EY015719 / EY / NEI NIH HHS / United States
R01 EY015719-06 / EY / NEI NIH HHS / United States

Weill Cornell Medicine
Hartman Institute for Therapeutic Organ Regeneration
1300 York Ave, Box 136 New York, NY 10065